Literature DB >> 29285436

Pentads and Hexads in Diabetes Care: Numbers as Targets; Numbers as Tools.

Sanjay Kalra1, Manash P Baruah2, Rakesh Sahay3, Kamal Kishor4.   

Abstract

Entities:  

Year:  2017        PMID: 29285436      PMCID: PMC5729661          DOI: 10.4103/ijem.IJEM_281_17

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.

INTRODUCTION

Most international organizations accept 7% as a reasonable glycated hemoglobin (HbA1c) value to aim for, while managing diabetes.[123] These organizations also suggest targets for fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) which should be achieved with optimal glucose-lowering treatment.[123] The three parameters, HbA1c, FPG, and PPG, together form the glycemic triad.[4] An understanding of the deleterious effects of glycemic variability (GV), mediated in part though oxidative stress, later led to the creation of a unified glucose tetrad concept.[5] This helped in improving clinical decision-making and in planning therapeutic interventions.

THE EARLY PENTAD

Further awareness of the needs of persons with diabetes informed the development of the glycemic pentad.[6] To the four glycemic parameters listed above, the pentad added quality of life (QoL). The glycemic pentad highlighted the importance of patient-reported outcomes (PROs) and underlined the relevance of the biopsychosocial model of health to diabetology. This pentad was a person-centered or patient-centered tool, meant to help achieve better outcomes. QoL was included as it is a measurable target, which contributes to long-term outcomes in diabetes care.

THE GLYCEMIC PENTAD

However, it was felt that QoL was not a glycemic parameter in the strict sense, and its inclusion was not warranted in a list of glycemic targets. Discussion on this topic helped prepared another framework, with five glucose-related variables: HbA1c, FPG, PPG, minimal GV, and minimal hypoglycemia.[78] This rubric is justified as all five investigations listed are related to glycemia, are independently related to cardiovascular outcomes, and are important targets of glucose-lowering therapy.

THE GLYCEMIC HEXAD

Fueled by enhanced focus on safety and tolerability of drugs, modern research has revealed subtle differences in the pathophysiology, presentation, and clinical implications of day-time hypoglycemia and nocturnal hypoglycemia. With this in mind, the glycemic pentad has been expanded to the glycemic hexad. The hexad lists three efficacy-oriented targets (HbA1c, FPG, and PPG) along with three safety-oriented goals (hypoglycemia, nocturnal hypoglycemia and GV). The six-point concept has been published as the Glycemic Sixer,[9] a term which resonates with cricket playing nations.

NUMBERS AS TOOLS

Number-based constructs such as the ones mentioned above are useful pedagogic tools, which also serve as frameworks upon which to plan and evaluate glucose-lowering therapy. Use of these models allows an treating physician to create a glucophenotype[10] or glucotype of an individual patient and choose the most appropriate therapy. The chosen treatment modalities help in achieving effective glucose control, in a safe and well-tolerated manner. This process has been facilitated by the development of modern insulin analogs, oral fixed-dose combination, and injectable glucagon-like peptide 1 receptors, which provide effective glucose control with low risk of hypoglycemia.

COMPREHENSIVE THERAPEUTIC APPROACH

Diabetes management, however, is much more than glucose-lowering alone. The glucocentric approach, in fact, has long been abandoned in favor of a comprehensive one, which targets multiple metabolic pathways and systems. The four main vasculometabolic targets[11] in diabetes care can be listed as the Metabolic Quartet (HbA1c, blood pressure, weight, and lipids).

THE THERAPEUTIC PENTAD

To this quartet, we suggest addition of PROs. Inclusion of PROs to this model reinforces patient-centered or person-centered care as a pillar of diabetes management. It reminds the physician that the person with diabetes care has a right to evaluate treatment regimens. This therapeutic pentad, or pentad of targets, provides guidance to the physician in planning management strategies [Figure 1].
Figure 1

The therapeutic pentad and pentuplets. BP: Blood pressure, HDL-C: High-density lipoprotein-cholesterol, LDC-C: Low-density lipoprotein-cholesterol

The therapeutic pentad and pentuplets. BP: Blood pressure, HDL-C: High-density lipoprotein-cholesterol, LDC-C: Low-density lipoprotein-cholesterol

THE FIVE PENTUPLETS

Each angle of this pentad can further be expanded, to serve as a teaching tool. This taxonomic structure is similar to that used by the ancient Indian physician, Atreya, who propounded Atreya's quadruple.[12] His quadruple lists four components, which are essential for optimal medical outcome. These are the physician, patient, drug, and attendant. For each stakeholder, Atreya describes four properties, thus creating four equipowerful quadruplets. Similarly, we can embellish the therapeutic pentad and create five quintuplets, to provide a comprehensive list of targets that must be addressed in diabetes management. This serves as an exhaustive list of evidence-based end-points, which contribute toward improving both biomedical and psychosocial, health, in persons with diabetes.

THE THERAPEUTIC HEXAD

Diabetology is an ever-evolving science[13] and its complexity is bound to grow. Insights into pathophysiology and salutogenic factors of diabetes, coupled with pharmaceutical developments, will increase the range of targets in diabetes management. We therefore propose a therapeutic hexad, or sixer, with six accompanying sextuplets. The sixth angle that we add is metabolic health, which includes nonglycemic investigations related to renal, hepatic, and metabolic parameters. The relationship of these “numbers” to cardiovascular outcomes is well documented and backed by evidence [Figure 2].
Figure 2

The therapeutic hexad and hexuplets. BP: Blood pressure, HDL-C: High-density lipoprotein-cholesterol, LDC-C: Low-density lipoprotein-cholesterol, LP (a): Lipoprotein (a), MAP: Mean arterial pressure, PRO: Patient-reported outcome

The therapeutic hexad and hexuplets. BP: Blood pressure, HDL-C: High-density lipoprotein-cholesterol, LDC-C: Low-density lipoprotein-cholesterol, LP (a): Lipoprotein (a), MAP: Mean arterial pressure, PRO: Patient-reported outcome

FROM TOOLS TO TARGETS

The rubrics discussed in this editorial are not ends in themselves. Rather, they utilize a numerophile strategy to prepare teaching tools which are easy to understand, teach, and learn [Table 1]. We note, with appreciation, usage of these models at national level across South and Southeast Asia and efforts of experts to achieve concordance of existing therapies with our models.[14] The models convert complex theory into simple (but not simplistic) knowledge, which informs pragmatic clinical decision-making. This, in turn, helps achieve optimal health for persons living with diabetes.
Table 1

Various glycemic and therapeutic models in diabetes care

Various glycemic and therapeutic models in diabetes care
  12 in total

1.  The gluco-phenotype.

Authors:  Sanjay Kalra; Yashdeep Gupta
Journal:  J Pak Med Assoc       Date:  2016-01       Impact factor: 0.781

Review 2.  Prandial glucose regulation in the glucose triad: emerging evidence and insights.

Authors:  Paul Beisswenger; Robert J Heine; Lawrence A Leiter; Alan Moses; Jaakko Tuomilehto
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

Review 3.  Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.

Authors:  Louis Monnier; Claude Colette; David R Owens
Journal:  Diabetes Metab Res Rev       Date:  2009-07       Impact factor: 4.876

4.  Hypoglycaemia in diabetes.

Authors:  Sanjay Kalra
Journal:  J Pak Med Assoc       Date:  2014-09       Impact factor: 0.781

5.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2017-01-17       Impact factor: 3.443

6.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

7.  Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.

Authors:  Amir Qaseem; Michael J Barry; Linda L Humphrey; Mary Ann Forciea; Nick Fitterman; Carrie Horwitch; Devan Kansagara; Robert M McLean; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2017-01-03       Impact factor: 25.391

Review 8.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.

Authors:  N M Kaplan
Journal:  Arch Intern Med       Date:  1989-07

Review 9.  Hypoglycaemia in anesthesiology practice: Diagnostic, preventive, and management strategies.

Authors:  Sanjay Kalra; Sukhminder Jit Singh Bajwa; Manash Baruah; Vishal Sehgal
Journal:  Saudi J Anaesth       Date:  2013-10

10.  Diabetes Care: Evolution of Philosophy.

Authors:  Sanjay Kalra; Manash P Baruah; Bharti Kalra
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
View more
  4 in total

1.  EADSG Guidelines: Insulin Therapy in Diabetes.

Authors:  Bahendeka Silver; Kaushik Ramaiya; Swai Babu Andrew; Otieno Fredrick; Sarita Bajaj; Sanjay Kalra; Bavuma M Charlotte; Karigire Claudine; Anthony Makhoba
Journal:  Diabetes Ther       Date:  2018-03-05       Impact factor: 2.945

Review 2.  Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care.

Authors:  Sanjay Kalra; Leszek Czupryniak; Gary Kilov; Roberta Lamptey; Ajay Kumar; A G Unnikrishnan; Aissa Boudiba; Mohamed Abid; Zhanay A Akanov; Ali Latheef; Mustafa Araz; Ralph Audehm; Silver Bahendeka; Naby Balde; Sandeep Chaudhary; Chaicharn Deerochanawong; Olufemi Fasanmade; Hinde Iraqi; Tint Swe Latt; Jean Claude Mbanya; Joel Rodriguez-Saldana; Ko Seung Hyun; Zafar A Latif; Maxim Lushchyk; Magdy Megallaa; Mohammed Wali Naseri; Nguyen Quang Bay; Kaushik Ramaiya; Hoosen Randeree; Syed Abbas Raza; Khalid Shaikh; Dina Shrestha; Eugene Sobngwi; Noel Somasundaram; Norlela Sukor; Rima Tan
Journal:  Diabetes Ther       Date:  2018-11-03       Impact factor: 2.945

3.  Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus.

Authors:  Sanjay Kalra; Nor Azmi Kamaruddin; Jayanti Visvanathan; Ravi Santani
Journal:  Eur Endocrinol       Date:  2019-08-16

4.  Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial.

Authors:  Pavle Vrebalov Cindro; Mladen Krnić; Darko Modun; Jonatan Vuković; Tina Tičinović Kurir; Goran Kardum; Doris Rušić; Ana Šešelja Perišin; Josipa Bukić
Journal:  JMIR Form Res       Date:  2022-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.